Tarsus Pharmaceuticals, Inc. has acquired Alkeus Pharmaceuticals, Inc. for $450.0 million, according to a definitive agreement announced today. The transaction, structured as an all-cash deal, brings Alkeus’s late-stage retinal disease program under Tarsus’s control, expanding the acquirer’s pipeline beyond its current commercial focus.
Alkeus, based in Cambridge, Mass., is a late-stage biopharmaceutical company dedicated to preserving the sight of individuals impacted by retinal diseases. Its lead candidate targets a genetic form of macular degeneration, a condition with no approved therapies. Tarsus, which develops and commercializes treatments for ophthalmic and dermatologic conditions, will integrate Alkeus’s clinical assets into its existing research and development framework.
The acquisition is strategic for Tarsus because it adds a high-value, late-stage asset to a portfolio that currently relies on a single approved product. By acquiring Alkeus, Tarsus gains access to a therapy that has completed pivotal trials, reducing the risk and time typically associated with early-stage drug development. The deal also broadens Tarsus’s presence in the retinal disease space, a therapeutic area with significant unmet medical need and growing patient populations.
For Alkeus, the transaction provides the financial and operational resources needed to navigate regulatory submission and potential commercialization, steps that are capital-intensive for a standalone biotech. Tarsus’s established commercial infrastructure in ophthalmology is expected to support a smoother launch if the therapy receives approval. The combined entity will focus on advancing the candidate through regulatory review while maintaining Tarsus’s existing product commitments.
The transaction is expected to close in the second half of this year, subject to customary closing conditions. Post-close, Tarsus will assume responsibility for all ongoing clinical and regulatory activities related to Alkeus’s pipeline. The combined company’s near-term priority will be preparing for a potential new drug application submission, with the goal of bringing the therapy to patients if approved.